Cargando…

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma

OBJECTIVE: In this post-hoc analysis, we evaluated anlotinib treatment-induced hypertension as a potential predictive factor of efficacy in esophageal squamous cell carcinoma (ESCC) patients. METHODS: A total of 109 patients enrolled in the anlotinib group in a phase 2 trial were included. The tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Yan, Xiao, Juxiang, Fang, Wentao, Lu, Ping, Fan, Qingxia, Shu, Yongqian, Feng, Jifeng, Zhang, Shu, Ba, Yi, Zhao, Yang, Liu, Ying, Bai, Chunmei, Bai, Yuxian, Tang, Yong, He, Jie, Huang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185854/ https://www.ncbi.nlm.nih.gov/pubmed/33724741 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0187

Ejemplares similares

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
por: Huang, Jing, et al.
Publicado: (2019)

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
por: Xu, Jianming, et al.
Publicado: (2022)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy
por: Cai, Jing, et al.
Publicado: (2021)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
por: Lin, Jingyang, et al.
Publicado: (2023)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
por: Jiang, Bailing, et al.
Publicado: (2019)

Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023)

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
por: Bai, Ming, et al.
Publicado: (2022)

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
por: Han, Chun, et al.
Publicado: (2021)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
por: Ma, Jianhui, et al.
Publicado: (2020)

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
por: Lu, Zhihao, et al.
Publicado: (2022)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
por: Zhen, Hongchao, et al.
Publicado: (2023)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
por: Zhou, Lingxiao, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
por: Tang, Lina, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma
por: Li, Ning, et al.
Publicado: (2022)

Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
por: Liu, Jiayong, et al.
Publicado: (2022)

Circ_0072088 Promotes Proliferation, Migration, and Invasion of Esophageal Squamous Cell Cancer by Absorbing miR-377
por: Fang, Na, et al.
Publicado: (2020)

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
por: Liu, Rongrui, et al.
Publicado: (2021)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
por: Wu, Xiaoyue, et al.
Publicado: (2022)

A phase I study investigation of metabolism, and disposition of [(14)C]-anlotinib after an oral administration in patients with advanced refractory solid tumors
por: Liu, Yiqian, et al.
Publicado: (2020)

Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
por: Zhao, Xiao-Han, et al.
Publicado: (2023)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
por: Qian, Yu, et al.
Publicado: (2022)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
por: Huang, Jia-Yi, et al.
Publicado: (2023)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Clinical study on postoperative recurrence in patients with pN1 esophageal squamous cell carcinoma
por: Guo, Xufeng, et al.
Publicado: (2015)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
por: Su, Ning, et al.
Publicado: (2022)

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
por: Yun, Tak, et al.
Publicado: (2011)

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
por: Kim, Hyo Song, et al.
Publicado: (2015)

Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
por: Wang, Jinwan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pks0ohf10trjquh45rrjb886na